Working… Menu

Lipoprotein Lipase Expression in Chronic Lymphocytic Leukemia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01460238
Recruitment Status : Completed
First Posted : October 26, 2011
Last Update Posted : March 28, 2019
American Cancer Society, Inc.
Information provided by (Responsible Party):
Frederick Lansigan, Dartmouth-Hitchcock Medical Center

Brief Summary:
The investigators hypothesize that Lipoprotein Lipase (LPL) expression on Chronic Lymphocytic Leukemia (CLL) cells will predict a more aggressive clinical course. The results from this proposal will validate the use of a novel antibody developed at Dartmouth-Hitchcock in CLL and will predict CLL patients that have a more aggressive form of the disease. The investigators work will also provide direct evidence that LPL is expressed on CLL cells and provides a critical source of fatty acids required by the CLL cells to grow and survive. Fatty acid metabolism may become a therapeutic target in CLL in the future.

Condition or disease
Chronic Lymphocytic Leukemia

Detailed Description:
The investigators plan to use a novel antibody developed at Dartmouth-Hitchcock Medical Center to characterize the expression of LPL in CLL. Peripheral blood from CLL patients will be analyzed by flow cytometry to detect the expression of LPL and to investigate if LPL expression correlates with a more aggressive type of CLL. The investigators propose that LPL protein expression on CLL cells is prognostic and that LPL and other proteins involved in fatty acid metabolism are critical for CLL cells to survive.

Layout table for study information
Study Type : Observational
Actual Enrollment : 29 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Lipoprotein Lipase Expression in Chronic Lymphocytic Leukemia
Study Start Date : October 2011
Actual Primary Completion Date : May 2018
Actual Study Completion Date : May 2018

Resource links provided by the National Library of Medicine

No treatment
No intervention. Each patient will have blood drawn at a standard of care venipuncture.

Primary Outcome Measures :
  1. LPL Protein Expression [ Time Frame: 1 year ]
    Determine the degree of LPL protein expression in CLL cells using a novel LPL antibody, correlate with IgHV mutation status, and compare this association with other prognostic markers

Secondary Outcome Measures :
  1. Fatty acid acquisition and synthesis [ Time Frame: 1 year ]
    Demonstrate that CLL cells also possess the enzymatic machinery for fatty acid acquisition and synthesis as shown by the expression of LPL, CD36, SDC1, and fatty acid synthase

Biospecimen Retention:   Samples With DNA
10 cc of peripheral blood and Archived lymph node tissue or bone marrow samples

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients at Dartmouth-Hitchcock Medical Center's Norris Cotton Cancer Center with CLL

Inclusion Criteria:

  • Diagnosis of CLL as per National Cancer Institute Working Group Guidelines
  • Patients undergoing routine blood draws as part of their ongoing follow up for CLL
  • 18 years or older
  • Ability to provide consent in English
  • Patient must have measurable disease as defined by an absolute lymphocyte count greater than 5,000/mm3 or have archived lymph node or bone marrow with CLL involvement.

Exclusion Criteria:

  • Patients who have received cytotoxic drug, oral or intravenous steroid or targeted antibody therapy for their CLL,
  • other hematologic malignancy or other disease process within the past 6 months are excluded.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01460238

Layout table for location information
United States, New Hampshire
Dartmouth-Hitchcock Medical Center
Lebanon, New Hampshire, United States, 03756
Sponsors and Collaborators
Dartmouth-Hitchcock Medical Center
American Cancer Society, Inc.
Layout table for investigator information
Principal Investigator: Frederick Lansigan, MD Dartmouth-Hitchcock Medical Center
Layout table for additonal information
Responsible Party: Frederick Lansigan, Assistant Professor of Medicine, Dartmouth-Hitchcock Medical Center Identifier: NCT01460238    
Other Study ID Numbers: D11065
First Posted: October 26, 2011    Key Record Dates
Last Update Posted: March 28, 2019
Last Verified: March 2019
Keywords provided by Frederick Lansigan, Dartmouth-Hitchcock Medical Center:
Lipoprotein Lipase
Chronic Lymphocytic Leukemia
Additional relevant MeSH terms:
Layout table for MeSH terms
Leukemia, Lymphoid
Leukemia, Lymphocytic, Chronic, B-Cell
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Leukemia, B-Cell